ArticleThe American journal of gastroenterology2026
Treatment Delays and Survival in Patients With Hepatocellular Carcinoma: A Multicenter Cohort Study.
Article in The American journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
introductionAlthough treatment delays have been reported for several cancers, fewer studies have described the prevalence, contributing factors, and impact on survival in patients with hepatocellular carcinoma (HCC). We aimed to evaluate these aspects in a multicenter cohort.
methodsWe conducted a retrospective cohort study of patients diagnosed with HCC from 2010 to 2018 across 4 US health systems. Treatment delay was defined as the first treatment >90 days after HCC diagnosis. Univariable and multivariable logistic regression analyses were performed to identify factors associated with treatment delays. The association between treatment delay and overall survival was evaluated using multivariable Cox regression analysis.
resultsAmong 1,561 eligible patients (median age 61.7 years, 75.0% men, 65.5% Barcelona Clinic Liver Cancer [BCLC] stage 0/A), treatment delays occurred in 357 (22.9%) patients. Treatment delays were most frequent with BCLC stage 0 (31.1%), followed by stage A (24.3%), stage B (22.6%), and stage C (13.6%). Men (OR 0.68, 95% CI 0.51-0.91) and patients with BCLC stage C HCC (vs stage A: OR 0.40, 95% CI 0.25-0.63) were less likely to experience delays, whereas those with BCLC stage 0 (vs stage A: OR 1.56, 95% CI 1.06-2.29) were more likely to experience delays. In a 6-month landmark analysis, survival did not differ between delayed vs timely treatment (HR 1.09, 95% CI 0.87-1.37). Median survival from the 6-month landmark was 12.1 months (IQR: 5.5-23.3) and 14.6 months (IQR: 5.1-30.0) for the treatment delay and timely treatment groups, respectively. DISCUSSION: Treatment delays exceeding 90 days occurred in over one-fifth of patients but were not associated with significant differences in survival.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.